AzTrials
AzTrials

Acute Respiratory Distress SyndromeNCT04369599

Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q System

A study testing V/Q System in people with Acute Respiratory Distress Syndrome and COVID-19, run by Emory University at 1 site in United States.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this pilot study is to measure the impact of non-invasive pneumatic manipulation of transthoracic pressure on oxygenation in patients with Acute Respiratory Distress Syndrome (ARDS) due to Coronavirus Disease 2019 (COVID 19) who are on mechanical ventilator support. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Acute Respiratory Distress Syndrome, COVID-19
What is being tested?
V/Q System
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
1 siteUnited States
Study dates
11 Aug 2020to Nov 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Presentation with acute respiratory distress syndrome (ARDS) requiring intubation with mechanical ventilator support. ARDS will be defined by the ratio of the partial pressure of oxygen in the patient's arterial blood (PaO2) to the fraction of oxygen in the inspired air (FiO2) as being < 300.
  • Ability of a Legally Authorized Representative (LAR) to provide consent on behalf of the patient.

Who cannot join

  • Presence of cutaneous wounds that would be compromised by the Vest including stage 3 or greater pressure ulcers and the presence of actively treated burns
  • Patients with pre-existing pulmonary hypertension and pulmonary fibrosis
  • Bony chest trauma within the last 10 days
  • Contraindications to esophageal manometry including recent esophageal trauma or surgery
  • Abdominal compartment syndrome
  • Active or recent gross hemoptysis
Show all 12Show fewer
  • Elevated intracranial pressure >20 mmHg
  • LAR refusal to participate
  • Severe Scoliosis
  • Morbidly obese (BMI >37)
  • Pregnant women
  • Unable to maintain oxygen saturation > 88%

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site
  • Emory University Hospital

    Atlanta, Georgia, 30322

Other trials in United States

About this study

The purpose of this pilot study is to measure the impact of non-invasive pneumatic manipulation of transthoracic pressure on oxygenation in patients with Acute Respiratory Distress Syndrome (ARDS) due to Coronavirus Disease 2019 (COVID 19) who are on mechanical ventilator support. This will be achieved by a pneumatic Vest placed around the chest wall of consenting patients who meet inclusion criteria. The Vest is essentially a non-invasive segmental device placed upon the anterior and posterior right and left aspects of the chest wall. The researchers have the ability to inflate and deflate the chambers of the Vest to achieve preset pressures as determined by the protocol and observe the patient's physiological response. Participants will have up to four hours of intervention with the study intervention, followed by 1 hour of post-intervention observation.

Read the detailed description

Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surfaced at the end of 2019, transmission has been rapid and particularly lethal. Death is most commonly due to ARDS which has been quoted as occurring in up to 42% of patients. The rapid lethality of the COVID-19 has emphasized the limitations of currently available therapies in the Intensive Care Unit. Traditional mechanical ventilator support, the use of inhaled and systemic pulmonary vasodilatory drugs, invasive monitoring, proning and extracorporeal membrane oxygenation (ECMO) to name a few, are all voracious consumers of resources and have culminated in at least $27 billion expenditure per annum in the US alone pre-virus. This fiscal burden has been far exceeded in the current pandemic. With patient numbers growing exponentially hospital resources are being rapidly surpassed with ICU's overflowing which is exacerbated by a national shortage of mechanical ventilators. New techniques are demanded to both treat patients and identify responders if medical resources are to be optimized.

Traditionally, patients present to the ICU and are intubated once a threshold of respiratory distress and failure is reached. Various maneuvers are initiated to optimize oxygen uptake by the lungs to prevent the onset of organ failure and death. At present, there are no effective bridging technologies providing intervention between intubation to these costly more complex techniques which are almost solely the purview of more technologically adept tertiary academic centers. Clinical practice is often empiric and driven by trial and error in this emerging disease, largely because there are presently no clinical tests to provide clinicians with any clear indication as to which and whether patients will respond to these more costly difficult procedures. This is in part due to the underlying pathophysiology of ARDS where there is a further "uncoupling" between bloodflow,(and hence uptake of oxygen), and healthy lung units which allow transfer and absorption of oxygen because of the damage to the alveoli. This phenomenon shifts physiologic Ventilation/Perfusion mismatch (V/Q mismatch) into a pathologic state. Since this phenomenon is worsened by diseased tissue, it is diffuse but, not uniform and response to therapy is difficult to determine based on current modalities. Thus, many therapies are therefore instituted purely by trial and error. Determination of appropriate candidates for advanced therapeutic techniques is critically important as they are not without risk and resource consumption. Patients who are profoundly hypoxic and fail traditional supine position support are "flipped" onto their abdomen to assume the prone position, a technique known as proning. This requires a team of at least 6 nurses, respiratory therapists and physicians who attempt to ensure that there are no adverse events. Such complications contribute to the morbidity and potential mortality of the maneuver and include accidental extubation (displacement of the endotracheal tube out of the trachea), disconnection from the ventilator, transient worsening hypoxia, hemodynamic instability, dislodgement of central and peripheral venous catheters to name a few. This is further compounded by the need for greater sedation which is itself associated with hemodynamic instability, aspiration, altered conscious state and an increase in acuity of monitoring making it much more labor intensive and expensive.

The researchers propose the development of a ventilation/ perfusion system, (V/Q System), a pneumatically driven device which can improve oxygenation by adjusting trans-thoracic pressure gradients. This is a new field of lung physiology which is only just being explored. However, the concept of noninvasive manipulation of lung mechanics and ventilation/perfusion mismatch is profoundly impactful as it potentially introduces a comparatively safe technique to address an otherwise fatal failure of lung function. The V/Q System represents an effort to optimize lung function without the risk of patient proning. If successful, improved oxygenation associated with the device has multiple clinical and economic ramifications. Initially, the device may obviate the need to more costly, time consuming and potentially morbid procedures. Future research may include investigating if the device may be utilized to identify both "responders" and "non-responders" to advanced therapeutic techniques and can help eliminate the "trial and error" approach in managing complex ARDS patients.

The study procedures will take up to 5 hours to complete for each participant enrolled. During this time, the participant will be sedated per standard ICU protocol. Each study participant will have up to 4 hours of intervention with the study V/Q System, followed by 1 hour of post-intervention observation.

Being tested
V/Q System
Medical subject headings
Respiratory Distress Syndrome, COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • V/Q SystemDevice

    With the patient supine, sedated, and hemodynamically stable, the Vest is placed upon the patient and secured by clinicians and staff. All chambers of the Vest will be inflated simultaneously. First inflation will be for one hour to a pressure of 0.4 psi. Subsequent inflations at 0.8 and finally 1.2 psi will be performed for one hour each. Participants will be treated for up to four hours and then will be observed for an additional hour.

Study groups in NCT04369599
Study groupRoleWhat they receive
V/Q SystemExperimentalParticipants with acute respiratory failure will undergo therapy with the V/Q System.
Receives: Device: V/Q System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Arterial Oxygenation Levels

    Improvement in oxygenation will be assessed by a demonstrated >20% increase in arterial oxygen levels after 180 minutes of treatment with the V/Q Vest, with two different levels of pressure. Normal levels of arterial oxygen range from 75 to 100 millimeters of mercury (mm Hg). Low oxygenation levels necessitate supplemental oxygen.

    Measured: Baseline, Hour 1, Hour 2, Hour 3, Hour 4, 1 Hour Post-intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Apr 2020
  2. Study start11 Aug 2020
  3. Primary completionNov 2026 (estimated)
  4. Study completionNov 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
15 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04369599
Sponsor's protocol ID
STUDY00000402
Other IDs
2025P009256
Status last verified
Jun 2026
First submitted
28 Apr 2020
Last updated
30 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Yes: All of the individual participant data collected during the trial will be made available for sharing, after deidentification.

Questions about this trial

What is this clinical trial studying?

A study testing V/Q System in people with Acute Respiratory Distress Syndrome and COVID-19, run by Emory University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 30 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Arterial Oxygenation Levels (time frame: Baseline, Hour 1, Hour 2, Hour 3, Hour 4, 1 Hour Post-intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in